The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Methods and compositions for treating hepatitis C virus

Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: 
Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.

Nucleoside phosphoramidate prodrugs

Nanotube on gate NhT structures and applications of such, including n2 crossbars requiring only 2n control lines. A non-volatile transistor device includes a source region and a drain region of a first semiconductor type of material and a channel region of a second semiconductor type of material disposed between the source and drain region. A gate structure is made of at least one of semiconductive or conductive material and is disposed over an insulator over the channel region. A control gate is made of at least one of semiconductive or conductive material. An electromechanically-deflectable nanotube switching element is in fixed contact with one of the gate structure and the control gate structure and is not in fixed contact with the other of the gate structure and the control gate structure. The device has a network of inherent capacitances, including an inherent capacitance of an undeflected nanotube switching element in relation to the gate structure. The network is such that the nanotube switching element is deflectable into contact with the other of the gate structure and the control gate structure in response to signals being applied to the control gate and one of the source region and drain region. Certain embodiments of the device have an area of about 4F2. Other embodiments include a release line is positioned in spaced relation to the nanotube switching element, and having a horizontal orientation that is parallel to the orientation of the source and drain diffusions. Other embodiments provide an n2 crossbar array having n2 non-volatile transistor devices, but require only 2n control lines.

Nanotube-on-gate fet structures and applications

A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Methods and compositions for treating flaviviruses and pestiviruses

The present invention relates to the use of nucleoside derivatives of formula I wherein B signifies a 9-purinyl residue B1 of formula or a 1-pyrimidyl residue B2 of formula wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof;
 
for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.

4'-substituted nucleoside derivatives as inhibitors of hcv rna replication

The present invention relates to the use of nucleoside derivatives of Formula (I) wherein B signifies a 9-purinyl residue B1 of Formula (B1) or a 1-pyrimidyl residue B2 of Formula (B2) wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the Hepatitis C Virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.

4'-substituted nucleosides

FIELD: organic chemistry, medicine, virology, pharmacy. ^ SUBSTANCE: invention relates to using 4'-substituted nucleosides of the formula (I): wherein R means hydrogen atom; R1 means alkyl possibly substituted with hydroxyl, and alkenyl, alkynyl, alkoxy, cyano or azido group; R2 means hydrogen atom or hydroxyl; R3 and R4 mean hydrogen atom, hydroxyl, alkoxy or halogen atom under condition that at least one radical among R3 and R4 means hydrogen atom; B means 9-purinyl residue of the formula (B1): wherein R5 means hydrogen atom; R6 means hydroxyl or -NHR8; R7 means hydrogen atom; R8 means hydrogen atom or phenylcarbonyl; or B means 1-pyrimidinyl residue of the formula (B2): wherein Z means oxygen atom (O); R10 means hydroxyl or -NHR8; R11 means hydrogen atom; R8 means a value given above. Also, invention relates to pharmaceutically acceptable salts of the compounds used for preparing a drug for treatment of diseases mediated by hepatitis C virus (HCV). Also, invention relates to a pharmaceutical composition for preparing a drug used in treatment of diseases mediated by hepatitis C virus (HCV), and to using this pharmaceutical composition for preparing a drug for treatment of diseases mediated by hepatitis C virus (HCV). ^ EFFECT: valuable medicinal properties of compounds and pharmaceutical composition. ^ 7 cl, 9 sch, 3 ex

4'-substituted nucleosides and pharmaceutical composition comprising thereof for preparing drug for treatment of hepatitis c virus (hcv)-mediated diseases

The present invention relates to the use of nucleoside derivatives of the general formula I , wherein B signifies a 9-purinyl residue B1 of the general formula , or a 1-pyrimidyl residue B2 of the general formula, wherein the other symbols are as defined in the Claims, and of pharmaceutically acceptable salts thereof; for the treatment of diseases mediated by the hepatitis C virus (HCV), for the preparation of a medicament for such treatment and to pharmaceutical compositions containing such compounds.

Medicament for the treatment of hepatitis C virus-mediated diseases

La presente invention concerne l'utilisation de derives de nucleoside representes par la formule (I) dans laquelle B designe un residu B1 de 9-purinyle de fornule (B1) ou un residu B2 de 1-pyrimidyle de formule (B2) dans lesquelles les symboles ont la definition qui leur est attribuee dans le descriptif, ainsi que des sels pharmaceutiquement acceptables de ces derives pour le traitement de maladies induites par le virus de l'hepatite C (HCV), et pour la preparation d'un medicament pour un tel traitement et de compostions pharmaceutiques renfermant de tels composes.

Devos Rene Robert

Papers

4'-substituted nucleoside derivatives as inhibitors of hcv rna replication

4'-substituted nucleosides

4'-substituted nucleosides and pharmaceutical composition comprising thereof for preparing drug for treatment of hepatitis c virus (hcv)-mediated diseases

Medicament for the treatment of hepatitis C virus-mediated diseases

Nucleosides substitues en 4